share_log

What Does The Future Hold For Aadi Bioscience, Inc. (NASDAQ:AADI)? These Analysts Have Been Cutting Their Estimates

What Does The Future Hold For Aadi Bioscience, Inc. (NASDAQ:AADI)? These Analysts Have Been Cutting Their Estimates

Aadi Bioscience, Inc.(納斯達克股票代碼:AADI)的未來會怎樣?這些分析師一直在下調預期
Simply Wall St ·  2023/11/16 02:11

The latest analyst coverage could presage a bad day for Aadi Bioscience, Inc. (NASDAQ:AADI), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. At US$4.71, shares are up 4.7% in the past 7 days. It will be interesting to see if this downgrade motivates investors to start selling their holdings.

最新的分析師報道可能預示着Aadi Bioscience, Inc.(納斯達克股票代碼:AADI)將迎來糟糕的一天,分析師全面下調了法定估計,這可能會讓股東有些震驚。該報告側重於收入估計,看來該業務的共識觀點已變得更加保守。股價爲4.71美元,在過去7天內上漲4.7%。看看降級是否會激勵投資者開始出售所持股份將很有趣。

After this downgrade, Aadi Bioscience's four analysts are now forecasting revenues of US$27m in 2024. This would be a meaningful 17% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$33m in 2024. It looks like forecasts have become a fair bit less optimistic on Aadi Bioscience, given the substantial drop in revenue estimates.

在此次降級之後,Aadi Bioscience的四位分析師現在預測2024年的收入爲2700萬美元。與過去12個月相比,這將使銷售額大幅增長17%。在最新估計之前,分析師預測2024年的收入爲3,300萬美元。鑑於收入預期大幅下降,看來對Aadi Bioscience的預測已經不那麼樂觀了。

See our latest analysis for Aadi Bioscience

查看我們對Aadi Bioscience的最新分析

earnings-and-revenue-growth
NasdaqCM:AADI Earnings and Revenue Growth November 16th 2023
納斯達克CM:AADI 收益和收入增長 2023 年 11 月 16 日

The consensus price target fell 6.4% to US$33.00, with the analysts clearly less optimistic about Aadi Bioscience's valuation following this update.

共識目標股價下跌6.4%,至33.00美元,在此更新之後,分析師對Aadi Bioscience的估值顯然不那麼樂觀。

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Aadi Bioscience's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 13% growth on an annualised basis. This is compared to a historical growth rate of 24% over the past three years. Compare this to the 669 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 16% per year. So it's pretty clear that, while Aadi Bioscience's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

獲取有關這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。很明顯,預計Aadi Bioscience的收入增長將大幅放緩,到2024年底,收入預計將按年計算增長13%。相比之下,過去三年的歷史增長率爲24%。相比之下,該行業其他669家擁有分析師資格的公司,預計這些公司的收入將以每年16%的速度增長。因此,很明顯,儘管Aadi Bioscience的收入增長預計將放緩,但預計其增長將與行業大致持平。

The Bottom Line

底線

The clear low-light was that analysts slashing their revenue forecasts for Aadi Bioscience next year. They're also forecasting for revenues to grow at about the same rate as companies in the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of Aadi Bioscience's future valuation. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Aadi Bioscience after today.

明顯的弱點是,分析師下調了對Aadi Bioscience明年的收入預期。他們還預測,收入的增長速度將與整個市場中的公司大致相同。共識目標股價大幅下跌,分析師似乎對最近的業務發展感到放心,這導致對Aadi Bioscience未來估值的估計降低。通常,一次降級可能會引發一連串的削減,尤其是在行業衰退的情況下。因此,如果今天之後市場對Aadi Bioscience變得更加謹慎,我們也不會感到驚訝。

Hungry for more information? We have estimates for Aadi Bioscience from its four analysts out until 2025, and you can see them free on our platform here.

想了解更多信息嗎?我們有四位分析師對Aadi Bioscience的估計,直到2025年,你可以在我們的平台上免費看到這些估計。

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

尋找可能達到轉折點的有趣公司的另一種方法是使用內部人士收購的成長型公司的免費清單,跟蹤管理層是買入還是賣出。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論